OptiNose — Q2 2022 Earnings Presentation
22 slides from OptiNose's earnings presentation, Aug 11, 2022
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n A u g u s t 1 1 , 2 0 2 2
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this
Slide 3: Q2 2022 Performance
optinose_ —— Q2 2022 Performance
Slide 4: Key Takeaways and Q2 2022 Highlights
4 Key Takeaways and Q2 2022 Highlights Completed Landmark ReOpen Trials in Q2 2022 Plan to Submit sNDA by the end of 2022 Improved Profitability of XHANCE Prescriptions by 12% in H1 2022 +21% XHANCE Net Revenue Growth H1 2022/H1 2021 +12% XHANCE Net Revenue per TRx Growth H1 2022/H1 2021 1,500 Physi
Slide 5: XHANCE as First FDA-approved Drug Treatment for Chronic Sinusitis Creates Growth Opportunities
5 Successful Development of XHANCE as the First FDA-approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Up to ~1 Million patients with nasal polyps (NP) are treated by specialty physicians in our current sales deployment $1B TAM $3B TAM Up to ~10 Million patie
Slide 6: ReOpen Program Update
optinose_ ——— ReOpen Program Update
Slide 7: Combined Symptom Score (Co-Primary Endpoint)
7 Combined Symptom Score (Co-Primary Endpoint) Improvement in combined symptoms with XHANCE; Consistent with NAVIGATE I and II 1 -0.81 -1.54* -1.74‡ -2.0 -1.8 -1.6 -1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS-placebo BID OPN-375
Slide 8: Average of Percentages of Opacified Volume
8 Average of Percentages of Opacified Volume (Ethmoid and Maxillary) Objective Evidence of Effect in Sinus Cavities by CT Scan; Co-Primary Endpoint 1.19 -7.00‡ -5.14♰ -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Baseline to W
Slide 9: Pooled Analysis Exacerbations (Key Secondary Endpoint)
9 Pooled Analysis Exacerbations (Key Secondary Endpoint) XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trials to reduce exacerbations for patients with chronic sinusitis 1 0.441 0.343 0.0 0.2 0.4 0.6 0.8 1.0 1.2 In ci de nc e Ra te R at io LS Mean Frequency of Exacer
Slide 10: Anticipated Next Steps
10 Anticipated Next Steps Meeting with FDA prior to data submission scheduled for the end of September – Meeting minutes available in fourth quarter Plan to submit sNDA by the end of 2022
Slide 11: Q2 2022 Commercial Update
optinose_ —— Q2 2022 Commercial Update
Slide 12: XHANCE New Prescriptions
12 XHANCE New Prescriptions Revised Co-Pay Assistance Program is Suppressing Unprofitable High-Deductible NRx in 2022 XHANCE New Prescriptions Increased 1% from Q2 2021 to Q2 2022 and 5% on a Year-to-Date Basis Estimated based on monthly prescription data from third parties and XHANCE preferred phar
Slide 13: XHANCE Total Prescriptions
13 XHANCE Total Prescriptions Revised Co-Pay Assistance Program is Suppressing Unprofitable High-Deductible TRx in 2022 XHANCE Total Prescriptions Increased 6% from Q2 2021 to Q2 2022 and 8% on a Year-to-Date Basis Estimated based on monthly prescription data from third parties and XHANCE preferred
Slide 14: XHANCE Market Share & Prescribers by Prescribing Frequency
14 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 21,000 physicians. Estimated based on monthly prescription data from thi
Slide 15: Q2 2022 Financial Update
optinose_ —— Q2 2022 Financial Update
Slide 16: Financial Review – XHANCE Net Revenue
16 Financial Review – XHANCE Net Revenue XHANCE Net Revenue Increased 12% from Q2 2021 to Q2 2022 and 21% on a Year-to-Date Basis $18.4 $20.6 Q2 '21 Q2 '22 ($M) +12% Net Revenue Net Revenue $29.3 $35.3 YTD June '21 YTD June '22 ($M) +21%
Slide 17: Financial Review – XHANCE Average Net Revenue per Prescription
17 $221 $235 Q2 '21 Q2 '22 Financial Review – XHANCE Average Net Revenue per Prescription XHANCE Average Net Revenue per TRx Increased from $221 to $235 from Q2 2021 to Q2 2022 and from $188 to $210 on a Year-to-Date Basis $188 $210 YTD June '21 YTD June '22 +12% Average Net Revenue per TRx Average
Slide 18: Full Year 2022 Financial Guidance and Pharmakon Agreement
18 Full Year 2022 Financial Guidance and Pharmakon Agreement XHANCE Net Revenue ‒ Expected to be between $85 - $92 million; Previously expected to be at least $90 million XHANCE Average Net Revenue per Prescription ‒ FY 2022 expected to exceed $220 Operating Expense (GAAP) ‒ Expected to be bet
Slide 19: Closing Remarks
optinose_ ——— Closing Remarks
Slide 20: Key Takeaways and Q2 2022 Highlights
20 Key Takeaways and Q2 2022 Highlights Completed Landmark ReOpen Trials in Q2 2022 Plan to Submit sNDA by the end of 2022 Improved Profitability of XHANCE Prescriptions by 12% in H1 2022 +21% XHANCE Net Revenue Growth H1 2022/H1 2021 +12% XHANCE Net Revenue per TRx Growth H1 2022/H1 2021 1,500 Phys
Slide 21: Investor Relations – Optinose Investor Contact
21 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267-521-0531 Investors@optinose.com As of June 30, 2022: – $78.3 million in cash – Long-term debt: $130 million – 83.0 million common shares o/s – 15.0 million options, warr
Slide 22: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n A u g u s t 1 1 , 2 0 2 2